After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
14 September 2024
Relativity-104 is revealed as a failure, and the phase 3 it just spawned could fail too.
13 September 2024
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
13 September 2024
Backed by a slender survival signal the industry’s only anti-fucosyl-GM1 MAb is to go pivotal.
12 September 2024
So far ASP3082 looks no better than Jiangsu HengRui’s straight KRAS G12D inhibitor.
12 September 2024
The small cap biotech Instil Bio tries to follow in Summit’s slipstream.
12 September 2024
Early data suggest that PD-(L)1 x VEGF bispecifics might challenge Keytruda in triple-negative disease.
Recent Quick take
- 21 August 2024
- 20 August 2024
- 20 August 2024
- 20 August 2024
- 19 August 2024
- 16 August 2024
- 15 August 2024
- 15 August 2024
- 14 August 2024
- 13 August 2024